» Articles » PMID: 11737710

Risk Factors for Severe Respiratory Syncytial Virus-associated Lower Respiratory Tract Infection in Children

Overview
Journal Pediatr Int
Specialty Pediatrics
Date 2001 Dec 12
PMID 11737710
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Respiratory syncytial virus (RSV) is the most important cause of viral lower respiratory tract infection that can be a life-threatening disease in infants and children. This study was conducted to look for independent risk factors for severe respiratory syncytial virus-associated lower respiratory tract infection (RSV-LRI) that required oxygen supplementation or mechanical ventilation.

Methods: Medical records of patients younger than 4 years hospitalized with RSV-LRI at Shizuoka Red Cross Hospital from July 1, 1995 to June 30, 1999 were reviewed. The patients were compared using univariate and multivariate logistic regression analysis.

Results: A total of 157 patients were hospitalized with RSV-LRI at Shizuoka Red Cross Hospital from the study time period. Of these, 20 patients (12.7%) were diagnosed with severe RSV-LRI. Subjects younger than 3 months of age had an odds ratio (OR) of 59.9 (95% confidence interval (CI) 14.7_244.0) for the dependent variable of severe RSV-LRI (P<0.0001). Subjects with a history of congenital heart disease also had an OR of 99.2 (95% C1 8.5-1160.1) (P<0.0005).

Conclusions: Infants younger than 3 months without any underlying diseases may be at high risk for severe RSV-LRI. Respiratory syncytial virus prophylaxis is needed not only for high-risk patients, but for healthy early infants.

Citing Articles

The Epidemiology, Clinical, and Economic Burdens of Respiratory Syncytial Virus Infections Amongst Hospitalized Children Under 5 Years of Age in Jordan: A National Multi-Center Cross-Sectional Study.

Abu-Helalah M, Al-Shatnawi S, Abu Lubad M, Al-Zayadneh E, Jdaitawi H, Harahsheh M Viruses. 2025; 16(12.

PMID: 39772177 PMC: 11680125. DOI: 10.3390/v16121867.


Long-Lasting Protection Induced by a Polyanhydride Nanovaccine against Respiratory Syncytial Virus in an Outbred Mouse Model.

Stephens L, Ross K, McLellan J, Narasimhan B, Varga S J Virol. 2022; 96(22):e0150222.

PMID: 36314826 PMC: 9683007. DOI: 10.1128/jvi.01502-22.


Considerations for a Respiratory Syncytial Virus Vaccine Targeting an Elderly Population.

Stephens L, Varga S Vaccines (Basel). 2021; 9(6).

PMID: 34207770 PMC: 8228432. DOI: 10.3390/vaccines9060624.


Nanoparticle vaccines against respiratory syncytial virus.

Stephens L, Varga S Future Virol. 2020; 15(11):763-778.

PMID: 33343684 PMC: 7737143. DOI: 10.2217/fvl-2020-0174.


The rate of viral transfer between upper and lower respiratory tracts determines RSV illness duration.

Gonzalez-Parra G, Dobrovolny H J Math Biol. 2019; 79(2):467-483.

PMID: 31011792 DOI: 10.1007/s00285-019-01364-1.